Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained virological response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to lower relapse(recurrence after stopping) compared with pegylated interferon alone (low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Sustained virological response · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
2 findings from 1 review
OR 1.72 [0.7, 4.21]
2 studies · 237 participants
Very low
Rate ratio 2.74 [1.4, 5.33]
2 studies · 237 participants
Very low
Chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes chronic HCV infection†‐ pegylated interferon‐alpha plus ribavirin… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Intervention not reported
Peg interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes peg interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin plus peg interferon vs.peg interferon · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes ribavirin plus peg interferon vs.peg interferon (very low certainty).
1 finding from 1 review
Intervention not reported
Interferon plus ribavirin vs.control · Participants with recurrent liver graft infection with hepatitis C virus.
It is very uncertain whether the intervention changes interferon plus ribavirin vs.control (very low certainty).
1 finding from 1 review
Intervention not reported
Ribavirin vs.interferon · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Ribavirin vs.placebo · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review
Intervention not reported
Retransplantation after start of therapy ‐ ribavirin vs.placebo · Participants with recurrent liver graft infection with hepatitis C virus.
1 finding from 1 review